Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial
Status:
Recruiting
Trial end date:
2022-08-02
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effects of canakinumab in preventing lung cancer in patients
who have high-risk pulmonary nodules. Canakinumab is a monoclonal antibody that may interfere
with the ability of tumor cells to grow and spread. Giving canakinumab may prevent the
development of lung cancer.